What's Happening?
LEO Pharma Inc., a leader in medical dermatology, has launched a new Direct-to-Consumer (DTC) campaign titled 'It’s GO time' to raise awareness about Chronic Hand Eczema (CHE) in the United States. The campaign promotes ANZUPGO® (delgocitinib) cream,
the first and only FDA-approved treatment for moderate to severe CHE. Chronic Hand Eczema is a debilitating skin condition affecting approximately one in ten adults in the U.S., characterized by itchy, painful, and blistered skin. Despite its prevalence, awareness remains low, with many patients unaware of the condition, leading to delays in diagnosis and treatment. The campaign aims to educate patients, increase brand awareness, and encourage discussions between patients and healthcare providers about ANZUPGO. The initiative is part of LEO Pharma's efforts to advance care in medical dermatology and support patient-provider conversations.
Why It's Important?
The launch of the 'It’s GO time' campaign is significant as it addresses the low awareness of Chronic Hand Eczema, a condition that affects daily activities and quality of life for many adults in the U.S. By promoting ANZUPGO, LEO Pharma is providing a targeted treatment option for those suffering from moderate to severe CHE, potentially improving patient outcomes. The campaign also highlights the importance of informed discussions between patients and healthcare providers, which can lead to better management of the condition. This initiative underscores LEO Pharma's commitment to advancing dermatological care and could lead to increased diagnosis and treatment of CHE, benefiting both patients and the healthcare system.
What's Next?
The 'It’s GO time' campaign will continue throughout the year, utilizing various media platforms such as streaming services and online ads to reach a broad audience. LEO Pharma aims to reinforce its leadership in dermatology by expanding awareness and encouraging more patients to seek appropriate treatment. The campaign's success could lead to further initiatives to address other under-recognized skin conditions. Additionally, increased awareness and diagnosis of CHE may prompt further research and development of new treatments, potentially expanding the market for dermatological products.
